남성호르몬보충요법에 따른 전립선질환의 관리 |
, , , , |
|
The management of prostatic diseases according to testosterone replacement therapy |
Jun Hyup Lee, Jung-Sik Huh, Young-Joo Kim, Kyung kgi Park, Sung Dae Kim |
|
Abstract |
Late onset hypogonadism (LOH) is defined as a biochemical syndrome associated with advancing age and characterized by a
deficiency in serum testosterone with or without decreased tissue sensitivity to testosterone. The precise role of testosterone in
the aging process of men remains unclear, and there have been few controlled clinical studies in aging men to investigate the
effects of testosterone replacement therapy on various organs and human functions known to deteriorate with age. The effect
of testosterone replacement therapy on the prostate is very important in terms of its safety in aging men. We recommend a
careful and individualized evaluation of present health problems combined with assessment of prostatic health (rectal
examination, transrectal ultrasound, and prostate specific antigen(PSA) measurement) be undertaken before testosterone
replacement is initiated. Perhaps the most controversial topic in the ongoing discussion of testosterone-replacement therapy is
the issue of risks of prostatic diseases. Recent reports suggesting increased risks associated with hormone replacement in
women have aroused concern that men receiving hormone replacement may also be vulnerable to increased health risks.
However, no large-scale, long-term studies have yet been initiated to assess the benefits and risks of testosteronereplacement
therapy in men, in part because of theoretical concern regarding the risks of therapy, especially possible
stimulation of prostate cancer by testosterone. The purpose of this review is to discuss what is known and not known regarding
the risks of testosterone replacement therapy and to provide recommendations for the monitoring of men receiving testosterone
treatment. |
Key Words:
late-onset, hypogonadism, prostate, monitoring |
|